GTGanna Tolstanova

Ganna Tolstanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ganna Tolstanova has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Tetyana Khomenko

    12 shared publications
  • Xiaoming Deng

    VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA

    12 shared publications
  • Zsuzsanna Sandor

    VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA

    10 shared publications
  • Longchuan Chen

    9 shared publications
  • Brankica Paunovic

    VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA

    8 shared publications
  • Sandor Szabo

    6 shared publications

Latest Publications

  • Open Access

    Association of plasma oxalate with computed tomography–derived stone characteristics in calcium oxalate nephrolithiasis

    by Natalia Stepanova, Andriy Sahalevych, Yaroslav Dubovyi, Taisa Dovbynchuk, Ganna Tolstanova

  • Open Access

    Association of SLC13A2 rs11567842 genotypes with kidney function in calcium–oxalate stone disease: a feasibility study in a Ukrainian cohort

    by Natalia Stepanova, Liliia Fishchuk, Yaroslav Dubovyi, Nataliia Gorovenko, Andriy Sahalevych, Taisa Dovbynchuk, Ganna Tolstanova

  • Structure–activity relationships in a series of dihydrouracil–JQ1 conjugates: discovery of highly potent BRD4 degraders

    by Oleh Shyshlyk, Vladyslav Stadnichenko, Oleksandr Diachenko, Iryna Chernysh, Anna Beshtynarska, Diana Alieksieieva, Diana Khotinets, Oleksii Oleksiak, Dmytro Lesyk, Yelyzaveta Yeremenko, et al.

    Comprehensive SAR studies in a series of phenyl dihydrouracil (PDHU)-derived PROTACs led to the discovery of novel nanomolar BRD4 degraders.

  • Open Access

    Intravenous 64zn-Aspartate Mitigates Neuroinflammation and Motor Dysfunction in an Lps-Induced Parkinson’s Disease Rat Model

    by Max Temnik, Mariia Rudyk, Alexandr Balakin, Sergey Gurin, Taisa Dovbynchuk, Roman Byshovets, Nataliia Dzubenko, Ganna Tolstanova, Larysa Skivka

    Emerging evidence links zinc dyshomeostasis to the pathogenesis of Parkinson’s disease (PD), highlighting the need to explore zinc-based interventions. Zinc has five stable isotopes, with 64Zn and 66Zn being the most abundant. Notably, healthy brain tissue is enriched in the lighter isotope 64Zn, while heavier isotopes are hypothesized to accumulate with age. This study examined the therapeutic potential of intravenously administered isotopically enriched 64Zn aspartate (64Zn-asp) in a rat model of PD induced by a single stereotactic intranigral injection of lipopolysaccharide (LPS, 10 μg), which simulates acute neuroinflammation followed by progressive neurodegeneration. Treatment effects were evaluated using behavioral assessments, immunological profiling, biochemical and molecular analyses, and histopathology. Rats treated with 64Zn-asp showed a pronounced anti-inflammatory shift in microglial/macrophage metabolic profiles and reduced reactive astrogliosis. These changes were accompanied by improved motor performance and decreased anxiety-like behavior. Immunohistochemistry confirmed preservation of dopaminergic neurons. Overall, these findings suggest that 64Zn-asp attenuates neuroinflammation and supports neuronal survival, indicating its potential as a candidate for disease-modifying strategies in PD. Graphical Abstract


  • Open Access

    Structure–Activity Relationships in a Series of Dihydrouracil-JQ1 Conjugates: Discovery of Highly Potent BRD4 Degraders

    by Oleh Shyshlyk, Vladyslav Stadnichenko, Oleksandr Diachenko, Iryna Chernysh, Anna Beshtynarska, Diana Alieksieieva, Diana Khotinets, Oleksii Oleksiak, Dmytro Lesyk, Angelina V. Biitseva, et al.

    A detailed study of structure-activity relationship (SAR) in a series of phenyl dihydrouracil (PHDU) derivatives as promising chemotypes for protein degrader discovery is reported. Evaluation of cereblon binding for several dozen PHDU-derived building blocks showed that over 20 compounds with various substituents at the phenyl ring showed over 50% displacement of labeled Thalidomide at 10 M. Most potent representatives bearing methyl substituent were used to synthesize 72 PROTACs by conjugating with JQ-1 though a series of linear linkers with or without additional heteroatoms. A series of assays (including binary and ternary complex formation, as well as cell-based BRD4 degradation) allowed establishing SAR trends regarding the linker nature and length. Compounds with (CH₂)₅, (CH₂)₆, and especially (CH₂)₁₁ linkers demonstrated the best results in both BRD4 degradation (DC₅₀ = 16–52 nM) and cell viability assays. The most potent representatives (2/5-Me-PDHU11) can be promising tools for biomedical research.

  • Systemic inflammation in Aβ1-40-induced Alzheimer’s disease model: New translational opportunities

    by Anastasiia Nefodova, Mariia Rudyk, Roman Dovhyi, Taisa Dovbynchuk, Nataliia Dzubenko, Ganna Tolstanova, Larysa Skivka


  • Open Access

    Pro-inflammatory effects of placebo neurosurgery in rats: age-related features

    by A. Nefodova, M. Rudyk, M. Pasichnichenko, R. Dovhyi, T. Dovbynchuk, G. Tolstanova, L. Skivka

    Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, affecting millions of people globally and causing significant disability and mortality. Animal models are the final step in completing preclinical studies and the most appropriate approach for gaining a thorough understanding of disease pathophysiology. Modeling of idiopathic AD and PD in rodents requires stereotactic injections of disease‑triggering substances. The placebo surgery group is an integral component of the design of these experiments in order to diminish study bias as a result of animal stress and non‑specific surgical impact. Inflammation is the most commonly reported non‑specific post‑surgery phenomenon, which can manifest in different ways in animals of different ages used in these experiments. Objective — to compare the long‑term pro‑inflammatory effects of placebo surgery, commonly employed for PD and AD modeling, in rats of different ages. Materials and methods. Adult male Wistar rats aged 4 and 14 months were used in the study. The placebo surgery consisted of a stereotactic unilateral intracerebral infusion of buffer solution. Before the placebo surgery, animals were anaesthetized using ketamine or xylazine administered intraperitoneally. Intact animals of both ages were used as a control. The evaluation of pro‑inflammatory effects of placebo surgery was conducted using biomarkers of local and systemic inflammation: metabolic polarization of phagocytes (microglia, peripheral blood cells), C‑reactive protein (CRP) plasma level, and systemic inflammation indexes calculated from the hemogram study. Results. In young lesioned animals, a pronounced pro‑inflammatory functional shift of microglia and signs of the resolution of systemic inflammation (an anti‑inflammatory skew of circulating phagocyte metabolism as compared to age‑matched intact controls) were observed in the long term after the placebo neurosurgery. In old intact animals, hematological and immunological markers of low‑grade systemic inflammation were observed. In lesioned old rats, residual neuroinflammation along with pronounced systemic inflammatory responses (leukocytosis, substantially increased SIRI and SII values, pro‑inflammatory metabolic shift of peripheral blood phagocytes as compared to age‑matched intact controls) were registered. Conclusions. The effects of placebo neurosurgical manipulations in rats depend on age. Meta‑inflammation inherent to aged rats is aggravated by non‑specific post‑surgery inflammation, leading to pronounced, persistent systemic inflammatory responses.


  • Open Access

    In Vitro Evaluation of In Silico Screening Approaches in Search for Selective ACE2 Binding Chemical Probes

    by Alexey V. Rayevsky, Andrii S. Poturai, Iryna O. Kravets, Alexander E. Pashenko, Tatiana A. Borisova, Ganna M. Tolstanova, Dmitriy M. Volochnyuk, Petro O. Borysko, Olga B. Vadzyuk, Diana O. Alieksieieva, et al.

    New models for ACE2 receptor binding, based on QSAR and docking algorithms were developed, using XRD structural data and ChEMBL 26 database hits as training sets. The selectivity of the potential ACE2-binding ligands towards Neprilysin (NEP) and ACE was evaluated. The Enamine screening collection (3.2 million compounds) was virtually screened according to the above models, in order to find possible ACE2-chemical probes, useful for the study of SARS-CoV2-induced neurological disorders. An enzymology inhibition assay for ACE2 was optimized, and the combined diversified set of predicted selective ACE2-binding molecules from QSAR modeling, docking, and ultrafast docking was screened in vitro. The in vitro hits included two novel chemotypes suitable for further optimization.


  • Open Access

    Pilot testing for long-term impact of glycerol-induced acute kidney injury on oxalate homeostasis in rats

    by Natalia Stepanova, Ganna Tolstanova, Iryna Akulenko, Valentyn Nepomnyashchyi, Svitlana Savchenko, Alexander Zholos, Mykola Kolesnyk

    There is a general lack of research on the long-term effects of acute kidney injury (AKI) on oxalate-degrading bacteria (ODB) and their total oxalate-degrading activity (ODA) in fecal microbiota. In the present pilot study, we separately evaluated the changes in the ODB number and their total ODA in fecal microbiota at 3-time points after glycerol-induced AKI. In addition, we assessed the interactions between AKI-induced renal histopathological changes and ODB, total fecal ODA, and plasma and urine oxalate concentrations in rats. Methods. The male Wistar rats (200-300 g, n = 20) on oxalate-free diet were randomly divided into 2 groups. After 24-h of water deprivation, experimental group 1 (n = 10) received an intramuscular injection of 50% glycerol (10 ml/kg of body weight), and group 2 (n = 10) served as a control. The numbers of ODB (incubated in a highly selective Oxalate Medium and determined using the culture method), total fecal ODA and urinary oxalate (UOx) excretion were measured after injection on days 8, 22 and 70. The method of redoximetric titration with a KMnO4 solution was adopted to evaluate total ODA in fecal microbiota. Renal injury was assessed by histopathology examination, serum creatinine plasma oxalic acid (POx) concentration and daily proteinuria levels after removing the animals from the experiment on day 70. Results. After glycerol injection on days 8 and 22, no differences were found in the numbers of ODB, their total fecal ODA, and UOx excretion level between the experimental and control groups. However, after AKI initiation on day 70, the numbers of ODB, total fecal ODA, and daily UOx excretion were significantly lower in the experimental group as compared with the control group. In addition, in 10 weeks following AKI, the number of ODB had a direct correlation with UOx excretion and an inverse correlation with POx and serum creatinine concentrations and daily proteinuria. Total ODA in fecal microbiota was directly associated with the percentage of renal interstitial fibrosis and the average glomerular volumes in the experimental rats. Conclusions: AKI had long-term negative effects on the quantitative and qualitative characteristics of ODB in fecal microbiota in rats. Moreover, the results of our study confirmed an increasing trend in total fecal ODA according to the aggravation of renal interstitial fibrosis and glomerular volume in rats’ kidneys. Further studies are warranted to gain more insight into the mechanism of oxalate homeostasis impairment in AKI.


  • Open Access

    Synbiotic supplementation and oxalate homeostasis in rats: focus on microbiota oxalate-degrading activity

    by Natalia Stepanova, Iryna Akulenko, Tetyana Serhiichuk, Taisa Dovbynchuk, Svitlana Savchenko, Ganna Tolstanova

    The present study aimed (i) to evaluate whether ceftriaxone treatment could affect not only intestinal oxalate-degrading bacteria number but also their total activity to degrade oxalate and influence oxalate homeostasis in rats, (ii) and to estimate the ability of commercially available inulin-contained synbiotic to restore fecal oxalate-degrading activity and ceftriaxone-induced disruption of oxalate homeostasis in rats. Twenty-eight female Wistar rats (200–300 g) were randomly divided into four groups (n = 7). Group 1 was treated with vehicle sterile water (0.1 ml, i.m., 14 days); Group 2 received synbiotic (30 mg/kg, per os, 14 days); Group 3 was treated with ceftriaxone (300 mg/kg, i.m., 7 days); Group 4 was supplemented with ceftriaxone and synbiotic. Oxalate-degrading bacteria number and their total activity, urinary and plasma oxalate concentrations were measured on days 1 and 57 after the treatment withdrawal. The redoximetric titration with KMnO4 was adopted to evaluate the total oxalate-degrading activity in highly selective Oxalate Medium. Ceftriaxone treatment reduced total fecal oxalate-degrading activity independently on oxalate-degrading bacteria number and increased urinary and plasma oxalate concentrations. The synbiotic had higher oxalate-degrading activity vs probiotics and was able to restore fecal oxalate-degrading activity and significantly decrease urinary oxalate excretion in antibiotic-treated rats. Total fecal oxalate-degrading activity but not oxalate-degrading bacteria number should be thoroughly examined in the future to develop predictive diagnostics methods, targeted prevention and personalized treatment in kidney stone disease. Synbiotic supplementation had a beneficial effect on the total oxalate-degrading activity of gut microbiota, which resulted in decreased UOx excretion in rats.